Lactation drug may cut breast cancer risk after childbirth, study finds

An international study suggests cabergoline, a lactation drug, may reduce breast cancer risk in mothers after childbirth, with users showing around 70% lower incidence. The finding could offer a new prevention strategy for high-risk women. Published in Cancer Discovery, the research analyzed health records from over 150,000 women in Spain and Norway. Mouse tests with BRCA1 and TP53 mutations showed tumor rates fell by about half after a single dose, supporting the human data. The drug appears to complete breast involution, the post-weaning cleanup process, reducing precancerous tissue. Clinical trials are planned for women with BRCA1 mutations, though current preventive options like hormone therapy or surgery have significant side effects.